Thrombolytic and antiplatelet action of Xanthinol nicotinate (Sadamin): Possible mechanisms

Journal of Physiology and Pharmacology

Volumn 49, Issue 2, 1998, Pages 241-249

  Bieron K ^a   Swies J ^a   Kostka Trabka, E ^a   Gryglewski, R J ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Antiplatelet activity; CAMP; CGMP; Hypontensive action; Nitric oxide; Prostacyclin; Thrombolysis; Xantinol nicotinate

Indexed keywords

CYCLIC AMP; CYCLIC GMP; INDOMETACIN; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE INHIBITOR; XANTHINOL NICOTINATE;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD CLOT LYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RAT; THROMBOCYTE AGGREGATION; VASODILATATION;

ADULT; AGED; ANIMALS; ARTERIAL OCCLUSIVE DISEASES; BLOOD PLATELETS; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RATS; RATS, WISTAR; VASODILATOR AGENTS; XANTHINOL NIACINATE;

EID: 0031849256     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Kaijser L, Eklund B, Olsson AG, Carlson LA. Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor indomethacin in man. Med Biol 1979; 57: 114-117.
2. Świe(combining ogonek)s J, Da(combining ogonek)browski L. Release of disaggregatory prostanoids into circulation by nicotinic alkohol, nicotinic acid and nicotinamide, Pol J Pharmacol Pharm 1984; 36: 653-657.
3. Dembińska-Kieć A, Korbut R, Bieroń K, Kostka-Tra(combining ogonek)bka E, Gryglewski RJ. Beta-pyridylcarbinol (Ronicol) releases prostacyclin-like substance into arterial blood in patients with arteriosclerosis obliterans. Pharm Res Commun 1983; 15: 377-385.
4. Radomski M, Świe(combining ogonek)s J, Gryglewski RJ. Disaggregatory action of phosphodiesterase inhibitors. Pharmacol Res Commun 1981; 13: 41-47.
5. Strada SJ, Hidaka H. Advances in second messenger and phosphoprotein research. In: The Biology Cyclic Nucleotide Phosphodiesterases, Vol. 25, New York, Raven Press, 1992.
6. Fears R, Ferres H, Haacke H, Mader C, Parwaresch MR. Decrease in LDL and increase in HDL concentrations in type II hyperlipoproteinaemic patients on low-dose combination therapy of cholestyramine and Complamin. Atherosclerosis 1988; 69: 97-101.
7. Kostka-Tra(combining ogonek)bka E, Goszcz A, Grodzińska L. et al. Antithrombotic action of Sadamin in patients with arteriosclerosis obliterans of the lower limbs. Terapia i Leki 1994; 6: 188-196.
8. Gryglewski RJ, Korbut R, Ocetkiewicz A, Stachura J. In vivo method for quantitation of antiplatelet potency of drugs. Naunyn Schmiedeberg's Arch Pharmacol 1978; 302: 25-30.
9. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929.
10. Wu KK, Hoak JC. A new method for the quantitative detection of platelet aggregates in patients with arterial insufficiency. Lancet 1974; ii, 924-926.
11. Kaulla von KN, Schultz RL. Methods for evaluation of human fibrinolysis. Am J Clin Pathol 1958; 29: 104.
12. Gryglewski RJ, Moncada S, Palmer RM. Bioassay of prostacyclin and endothelium-derived relaxing factor (EDRF) from porcine aortic endothelial cells. Br J Pharmacol 1986; 87: 685-694.
13. De Nucci G, Gryglewski RJ, Warner TD, Vane JR. Receptor-mediated release of endothelium-derived relaxing factor (EDRF) and prostacyclin from bovine aortic endothelial cells is coupled. Proc Natl Acad Sci USA 1988; 85: 2334-2338.
14. Gryglewski RJ. Interactions between nitric oxide and prostacyclin. Semin Thromb Hemost 1993; 19: 158-166.
15. Gryglewski RJ, Chłopicki S, Świe(combining ogonek)s J, Niezabitowski P. Prostacyclin, nitric oxide, and atherosclerosis. Ann NY Acad Sci 1995; 748: 194-206.
16. Gryglewski RJ. Interactions between endothelial mediators. Pharmacol Toxicol 1995; 77: 1-9.
17. Gryglewski RJ, Korbut R, Tra(combining ogonek)bka-Janik E, Zembowicz A, Trybulec M. Interaction between NO donors and iloprost in human vascular smooth muscle, platelets and leukocytes. J Cardiovasc Pharmacol 1989; 14: Suppl. 11, S124-S128.
18. 2) and EDRF (NO). In: Thrombosis and Haemorrhagic Disorders. H. Sinzinger and H. Vinazzer (eds.), Wurzburg, Schmitt&Meyer GmbH, 1990, pp. 413-415.
19. Gryglewski RJ, Korbut R, Kalecińska A, Zembowicz A. Interaction between stimulators of adenylate and guanylate cyclases in human leukocytes, platelets and arteries. Int J Tissue React 1989; 11: 269-275.
20. Gryglewski RJ. Secretory function of vascular endothelium and its implication in the action of vasoactive drugs. Pol J Pharmacol Pharm 1990; 42: 219-236.
21. Gryglewski RJ. Nitric oxide and atherosclerosis. Thrombotic and Haemorrhagic Disorders 1990; 2: 1-9.
22. Grodzińska L, Basista M, Ke(combining ogonek)dzior A, Korbut R, Kostka-Tra(combining ogonek)bka E, Gryglewski R. Fibrinolytic activity and the effects of beta-pyridylcarbinol (Ronicol) in patients with arteriosclerosis obliterans. Tromb Haemost 1983; 50: 797-781.
23. Gryglewski RJ, Bieroń K, Dembińska-Kieć A, Kostka-Tra(combining ogonek)bka E, Zembowicz A. Interaction between prostacyclin and molsidomine in blood cells and plasma. In: Adv. Prostagl. Thromb. Leukotr. Res., vol. 21. B. Samuelsson et al. (ed.), New York, Raven Press, 1990, pp. 655-658.
24. Bieroń K, Grodzińska L, Kostka-Tra(combining ogonek)bka E, Gryglewski RJ. Prostacyclin and molsidomine synergise in their fibrinolytic and anti-platelet actions in patients with peripheral arterial disease. Wien Klin Wochenschr 1993; 105: 7-11.